Custo-efetividade da vacina contra influenza quadrivalente baseada em células comparada com a trivalente baseada em ovo do Programa Nacional de Imunizações brasileiro

Ballalai, Isabella

doi:10.21115/jbes.v13.n2.p136-44

Cited by 2 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that vaccination with QIVc would reduce the number of seasonal influenza cases, complications, hospitalizations, and deaths compared to QIVe. Endorsing this evidence, several studies evaluated the cost-effectiveness of QIVc compared to QIVe worldwide and demonstrated similar findings [ 17 , 18 , 19 , 21 ]. This result can be attributed to the fact that cell-based influenza vaccines can be more effective than traditional egg-based influenza vaccines, favoring several populations and clinical and economic outcomes [ 17 ].…”

Section: Discussionmentioning

confidence: 74%

“…Given the clinical and epidemiological circumstances of influenza, a one-year time horizon was adopted. The methodology was similar to previously published cost-effectiveness analyses of influenza vaccination in South America [ 4 , 19 , 25 , 26 ].…”

Section: Methodsmentioning

confidence: 99%

“…The probabilistic sensitivity analysis was conducted by varying all the model’s parameters simultaneously to a random value, according to its distribution: costs were assumed to have a gamma distribution; percentage and utility parameters were assumed to have a beta distribution, similar to a previous study [ 19 ]. In this sensitivity analysis, 10,000 Monte Carlo second-order simulations were performed.…”

Section: Methodsmentioning

confidence: 99%

“…The cost-effectiveness of QIVc has been reported for the United States (US) [ 16 , 17 ], Spain [ 18 ], Brazil [ 19 ], the United Kingdom (UK) [ 20 ], and Germany [ 21 ]. In the UK, Kohli et al reported the cost-effectiveness of extending QIVc vaccination regimen from at-risk to low-risk adults between 50 and 64 years of age [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…QIVc was found to be a cost-effective alternative to QIVe in a seasonal influenza analysis using an economic model on high-risk subjects aged between 9 and 64 years in Spain [ 18 ]. In Brazil, replacing the trivalent vaccine with QIVc in the Brazilian National Immunization Program proved to be cost-effective [ 19 ]. Corroborating this evidence, reports from real-world data from the US during the 2017–2020 influenza season demonstrated that QIVc was significantly more effective in preventing influenza-related hospitalizations and emergency room visits, all-cause hospitalizations, and any event-associated hospitalizations and emergency visits compared to QIVe.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Urueña

Micone

Magneres³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Urueña

Micone

Magneres³

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

Genital infection by Human papillomavirus (HPV) in women from Santa Catarina/Brazil

Fedrizzi

Steffens

Menezes³

et al. 2022

J Bras Doenças Sex Transm

View full text Add to dashboard Cite

Introduction: Human Papillomavirus (HPV) infection is the most common sexually transmitted infection in women. About 80% of sexually active women will have contact with this virus at some point in their lives. Most infections will be transient, but when the infection becomes persistent and associated with a high oncogenic risk of Human Papillomavirus, there may be progression to cancer, especially cervical cancer. The best way to prevent Human Papillomavirus infection is through the use of vaccines, which have been available to the public in Brazil since 2014. Objective: This study aimed to assess the most prevalent types of Human Papillomavirus in the state of Santa Catarina, Brazil, and its mesoregions and if the majority of diagnosed types are contained in the Human Papillomavirus vaccines currently available on the market. Methods: A total of 20,000 Human Papillomavirus tests were evaluated for the diagnosis of genital Human Papillomavirus infection in women from the state of Santa Catarina, Brazil. The prevalence of infection was evaluated according to age and the city of origin of the exams. Human Papillomavirus detection was performed using molecular biology tests, such as hybrid capture (for diagnosis of the Human Papillomavirus group, high or low oncogenic risk) and polymerase chain reaction (viral genotyping) techniques. Results: The diagnosis of Human Papillomavirus infection was performed on women between 1 and 102 years of age. The age with the highest Human Papillomavirus positivity, as expected, was 20–25 years (45.6%) and the lowest after 70 years (7.1%). The highest Human Papillomavirus positivity of the exams was observed in the Serrana region of Santa Catarina state (58.9% of the exams). A high-oncogenic-risk Human Papillomavirus was detected in 93% of positive samples and was the most frequent in all age groups. Mixed infection (high- and low-risk Human Papillomavirus) was more prevalent in the 66–70 age group (29.3%) and in the Southern Region of Santa Catarina (26.4%). The most frequent genotypes in the state of Santa Catarina were non-16/18 high oncogenic risk Human Papillomavirus (76.9% of positive cases). Human Papillomavirus 16 was found in 17.1% of positive cases and Human Papillomavirus 18 in 6.6%. Conclusion: The most prevalent types of Human Papillomavirus in the state of Santa Catarina in the past 6 years are the non-16/18 high oncogenic risk Human Papillomavirus types, which are viral types not covered by the current Human Papillomavirus vaccines available in Brazil.

show abstract

Custo-efetividade da vacina contra influenza quadrivalente baseada em células comparada com a trivalente baseada em ovo do Programa Nacional de Imunizações brasileiro

Cited by 2 publications

References 18 publications

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Genital infection by Human papillomavirus (HPV) in women from Santa Catarina/Brazil

Contact Info

Product

Resources

About